Program
Rifaximin
Also written as “Rifaximin 200 mg Tablet”, “Low Dose Rifaximin ER” and “High Dose Rifaximin ER”.
Its studies are mostly in Diarrhea · Hepatic Encephalopathy · Rosacea · Anemia, Sickle Cell · Crohn Disease, led by 4 companies.
Drug pageRifaximin: every studyAll 150 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bausch Health Companies | 161 open or running | phase 4since Apr 16, 2013 | Dec 22, 2005 | Apr 20, 2027phase 4 · NCT07285785 |
| Alfasigmaits history only | 40 open or running | phase 2since Feb 19, 2015 | Feb 19, 2015 | none ahead |
| Novartisits history only | 10 open or running | phase 3since Sep 29, 2016 | Sep 29, 2016 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Jul 9, 2015 | Jul 9, 2015 | none ahead |
Also a collaborator on its studies: bioRASI, Cromsource and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bausch Health Companies only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 22, 2005First study: phase 2 study in Irritable Bowel SyndromeFirst studyNCT00269412 · 525 enrolled · United States
- Dec 22, 2005Phase 3 study in Clostridium InfectionsNCT00269399 · 237 enrolled · United States
- Feb 28, 2006Phase 3 study in Hepatic EncephalopathyNCT00298038 · 299 enrolled
- May 17, 2006Phase 3 study in DiarrheaNCT00328380 · 660 enrolled · United States
- May 27, 2008Phase 3 study in Hepatic EncephalopathyNCT00686920 · 322 enrolled · United States, Canada
- Jul 16, 20082 phase 3 studiesNCT00731679, NCT00724126
- Aug 24, 2008Phase 3 study in DiarrheaNCT00742469 · 210 enrolled · Mexico
- Aug 27, 2008Phase 1 study in PharmacokineticNCT00743912 · 24 enrolled
- Feb 27, 2012Phase 3 study in DiarrheaNCT01543178 · 2,583 enrolled · United States, Germany, United Kingdom
- Apr 16, 20132 phase 4 studies in Hepatic EncephalopathyNCT01842581, NCT01846663
- Jul 17, 2013Phase 2 study in Liver CirrhosisNCT01904409 · 420 enrolled · United States, Russian Federation
- Jan 22, 2019Phase 4 study in Severe Hepatic ImpairmentNCT03818672 · 5 enrolled · United States
- Oct 18, 2021Phase 2 study in Anemia, Sickle CellNCT05098028 · 44 enrolled · United States, Canada, Kenya
- Dec 2, 2025Phase 4 study in DiarrheaNCT07285785 · 54 planned · United States
Ahead
- Apr 20, 2027Primary completion: phase 4 study in DiarrheaNCT07285785
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial DNA-directed RNA polymerase inhibitor”ChEMBL 37, by rule
Studies
All 16 Bausch Health Companies leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07285785Diarrhea · United States | 4 | Recruiting | Apr 20, 2027 | 54 |
| NCT05098028Anemia, Sickle Cell · United States, Canada, Kenya | 2 | Completed | Sep 4, 2023 | 44 |
| NCT03818672Severe Hepatic Impairment · United States | 4 | Terminated | Feb 2, 2020 | 5 |
| NCT01904409Liver Cirrhosis · United States, Russian Federation | 2 | Completed | Jun 2015 | 420 |
| NCT01846663Hepatic Encephalopathy · United States | 4 | Terminated | Feb 22, 2016 | 6 |
| NCT01842581Hepatic Encephalopathy · United States | 4 | Completed | Dec 17, 2014 | 222 |
| NCT01543178Diarrhea · United States, Germany, United Kingdom | 3 | Completed | Jun 2014 | 2,583 |
| NCT00743912Pharmacokinetic | 1 | Completed | Oct 2008 | 24 |
| NCT00742469Diarrhea · Mexico | 3 | Completed | Sep 2005 | 210 |
| NCT00724126Diarrhea · United States | 3 | Completed | Aug 2009 | 637 |
| NCT00731679Abdominal Pain · United States, Canada | 3 | Completed | Aug 2009 | 623 |
| NCT00686920Hepatic Encephalopathy · United States, Canada | 3 | Completed | Dec 8, 2010 | 322 |
| NCT00328380Diarrhea · United States | 3 | Completed | Dec 2006 | 660 |
| NCT00298038Hepatic Encephalopathy | 3 | Completed | Aug 15, 2008 | 299 |
| NCT00269412Irritable Bowel Syndrome · United States | 2 | Completed | Aug 2007 | 525 |
| NCT00269399Clostridium Infections · United States | 3 | Completed | Dec 2008 | 237 |
How it is read
Names in the registry
- “Rifaximin”, 12 entries
- “Rifaximin 200 mg Tablet”, 1 entry
- “Low Dose Rifaximin ER”, 1 entry
- “High Dose Rifaximin ER”, 1 entry
- “Rifaximin delayed release tablets”, 1 entry
Conditions, from the studies’ own filings
- Diarrhea, 7 studies
- Hepatic Encephalopathy, 4 studies
- Rosacea, 2 studies
- Anemia, Sickle Cell, 1 study
- Crohn Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.